Reviva Pharmaceuticals Holdings (RVPH) Change in Accured Expenses (2021 - 2026)

Reviva Pharmaceuticals Holdings has reported Change in Accured Expenses for 6 years, with the latest figure at -$249652.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 80.74% year-over-year to -$249652.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.0 million (down 91.41% YoY) and the FY2025 annual result came in at -$4.0 million, up 22.04% from the prior year.
• Change in Accured Expenses improved to -$249652.0 in Q1 2026 per RVPH's latest filing, from -$308848.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $2.6 million in Q2 2023 and troughed at -$4.9 million in Q1 2024.
• A 5-year average of $123687.6 and a median of $113673.0 in 2025 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses soared 1039.91% in 2023, then slumped 6338.01% in 2025.
• Over 5 years, Change in Accured Expenses stood at $2.4 million in 2022, then tumbled by 37.66% to $1.5 million in 2023, then tumbled by 154.14% to -$813375.0 in 2024, then soared by 62.03% to -$308848.0 in 2025, then gained by 19.17% to -$249652.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$249652.0, -$308848.0, and -$2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.